Aifred: The AI Tool Helping Clinicians Finally Personalise Depression Treatment
What is Aifred? Aifred is a deep-learning clinical decision support system that predicts individualised remission probabilities for antidepressant and combination treatments to help clinicians choose more effective MDD therapies. The platform ingests patient demographics, clinical history and standardised questionnaires, and returns ranked treatment options with predicted probability scores — intended to reduce trial-and-error prescribing and […]
Feature Categories
What is Aifred?
Aifred is a deep-learning clinical decision support system that predicts individualised remission probabilities for antidepressant and combination treatments to help clinicians choose more effective MDD therapies. The platform ingests patient demographics, clinical history and standardised questionnaires, and returns ranked treatment options with predicted probability scores — intended to reduce trial-and-error prescribing and speed clinical response.
Aifred Health has been developed and validated on pooled clinical-trial and real-world datasets, piloted in simulation and feasibility studies, and deployed in a multicenter cluster randomised trial showing improved remission outcomes in the active arm. The company is pursuing regulatory approvals and enterprise rollouts with clinician-focused workflow integrations.
Why Leading Healthcare Teams Trust Aifred
- Health Canada approval for the sale and commercialisation of its AI-driven clinical decision support device achieved in September 2024
- Granted key U.S. patent for the use of artificial intelligence to guide treatment selection in April 2023
- Won first place in North America and second place worldwide in the prestigious XPRIZE competition
- Successfully completed multi-site clinical trial in collaboration with the US Department of Veterans Affairs and leading centers of excellence across North America
- 92% of patients found the tool easy to use, and 86% of doctors found the AI model helpful in making treatment decisions in real-world studies
- Working towards FDA regulatory approval in the U.S. for 2025 following Health Canada approval
- Uses deep learning models and data pre-processing techniques developed in-house for personalised treatment predictions
- Focused on operationalising best evidence guidelines together with AI-based insights to support better treatment management
- Addresses a critical healthcare need affecting over 300 million people worldwide suffering from depression
- Partnership with established software development firm Spiria for scalable SaaS solution development while maintaining compliance requirements
Top 3 Pain Points Aifred Fixes in Healthcare
| Problem | How Aifred Solves It |
|---|---|
| 1. Trial-and-error in antidepressant prescribing | Predicts individualized remission probabilities for multiple treatments, reducing guesswork in medication selection. |
| 2. Slow time-to-remission for depression patients | Helps clinicians choose effective therapies earlier, shortening the treatment cycle and improving speed of recovery. |
| 3. Clinician burden in treatment decision-making | Provides AI-powered clinical decision support integrated into workflows, giving data-driven guidance at the point of care. |
Feature Category Summary: Aifred
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | Aifred is an AI-driven clinical decision support software medical device for the treatment of moderate to severe major depression that has received a Canadian Medical Device License (Health Canada approval) and has completed a North American regulatory approval clinical trial, with the company initiating US and Canadian regulatory approval processes and later communicating that the FDA has formally confirmed its platform as a non-regulated clinical decision support tool, demonstrating explicit engagement with medical-device regulators and regulatory strategies. | YES |
| Clinical Trial Support | Aifred has been the focus of a North American regulatory approval clinical trial and earlier simulation-centre and feasibility studies, where the platform itself is the investigational device, but there is no explicit evidence that Aifred provides generic tools or modules for designing, recruiting, monitoring, or reporting third-party clinical trials. | NA |
| Supply Chain & Quality | No public documentation found indicating that Aifred includes features for pharmaceutical or device supply-chain integrity, counterfeit detection, manufacturing QA, or GMP/GQP quality-release workflows; the product is positioned entirely as a clinical decision support tool for depression treatment choice. | NA |
| Efficiency & Cost-Saving | Company communications and research summaries state that the platform replaces a difficult, time-consuming trial-and-error approach to antidepressant selection by using patient- and clinician-completed questionnaires to personalize treatment choice in real time, with the goal of improving outcomes and reducing the time and effort required for clinicians managing moderate to severe depression. | YES |
| Scalable / Enterprise-Grade | Aifred is described as a platform that can be integrated into routine clinical workflows using standard questionnaires and deployed across multiple clinical centers, including US Veterans Affairs hospitals and leading centers of excellence during its North American trial, but there is no explicit evidence of production-scale enterprise SaaS deployments in large pharma or biotech organizations. | NA |
| HIPAA Compliant | Available public materials emphasize regulatory engagement and data protection in general terms, but there is no explicit statement that the Aifred platform is HIPAA compliant or certified, nor detailed descriptions of HIPAA-aligned technical and organizational controls. | NA |
| Clinically Validated | Peer-reviewed work describes simulation-centre and feasibility studies assessing acceptability, workflow impact, and physician–patient interaction for the AI-powered CDSS, and company press releases report completion of a North American regulatory approval clinical trial in major depression that demonstrated significantly improved remission rates and clinical benefits when the CDSS was used versus usual care. | YES |
| EHR Integration | Press releases explain that Aifred uses patient and clinician questionnaires that integrate into clinical workflow and that the platform can be used across family practice, nurse practitioner, and psychiatry settings, but there is no explicit description of technical integration with named EHR systems or standards such as HL7 or FHIR. | NA |
| Explainable AI | The research page notes that the team rigorously tests models to avoid propagating biases and is implementing and pioneering new approaches to model interpretability, aiming to provide interpretable AI outputs to clinicians so they can understand the factors influencing treatment recommendations. | YES |
| Real-Time Analytics | Statements from company leadership highlight that the platform allows decisions to be made in real time during clinical encounters using readily available questionnaire data, but there is no evidence of broader real-time analytics features such as continuous population dashboards or operational analytics beyond per-patient decision support. | NA |
| Bias Detection | The research page states that Aifred rigorously tests its models to ensure they do not propagate biases, but there is no public documentation of a dedicated bias-detection feature in the product that quantifies and displays performance across demographic or clinical sub-cohorts. | NA |
| Ethical Safeguards | Published studies and company communications emphasize that the AI-CDSS is intended to support, not replace, clinician judgment and that development involved collaboration with clinicians and centers of excellence to ensure responsible use, yet there is no explicit description of built-in governance controls such as configurable consent management, enforced human-in-the-loop overrides, or technical use-case restrictions in the deployed software. | NA |
Risks & Limitations: Aifred
-
Effect-size uncertainty: published pilot effect sizes vary; real-world benefit hinges on clinician adoption, measurement fidelity, and integration into care pathways.
-
Data-dependence & bias: performance depends on input data fidelity and representativeness; demographic and comorbidity biases must be evaluated during piloting.
-
Regulatory & medico-legal: CDSS outputs are advisory; procurement should document liability, clinician oversight, and validation/monitoring processes.
-
Complementary diagnostics: pharmacogenomics and comorbidity management remain necessary adjuncts; CDSS should be used as part of a multi-modal care approach.
Share This AI Tool
Get a neutral, no obligation view of whether this AI tool fits your portfolio
